T u b e r c u l o s i s
ğŸŒ  E p i d e m i o l o g y  a n d  G l o b a l  B u r d e n  o f  T B
This section f ocuses on the glob al pr e v alence, incidence, and r isk f act ors  
associat ed with T uber culosis î‚TBî‚‚. I t highlight s the dise ase 's imp act and the  
populations most af f ect ed.
1î‚’ TB Epidemiology Ov er vie w
Epidemiology î‚’ The stud y of the distr ibution and det er minant s of he al th-r elat ed  
st at es or e v ent s in specified populations, and the applic ation of this stud y t o  
the contr ol of he al th pr oblems.
1î‚’ Glob al Incidence and Pr e v alence
Global Bur den î‚’ TB r emains a major glob al he al th pr oblem, with millions of ne w  
c ases annuall y .Â  Incidence î‚’ The rat e of ne w c ases of TB in a giv en population  
o v er a specific per iod.Â  Pr e v alence î‚’ The t ot al number of e xisting c ases of TB in  
a population at a specific point in time.Â  Estimat ed 1. 6 Billion Inf ect ed î‚’  
Appr o ximat el y one-quar t er of the w or ld's population is estimat ed t o be inf ect ed  
withÂ  M y cobact er ium tuber culosis Â î‚MTBî‚‚.Â  Activ e TB Cases î‚’ Ar ound 10 . 6 million  
people w or ldwide ha v e activ e TB dise ase, manif esting r espirat or y  
sympt oms.Â  Childhood TB î‚’ About 10% of activ e TB c ases occur in childr en.
2î‚’ Mor t alit y and Imp act
Leading Cause of Death î‚’ TB is a signific ant c ause of de ath glob all y , especiall y  
among those co-inf ect ed with HIV .Â  Mor t alit y R at es î‚’ High in cer t ain r egions,  
especiall y in those with limit ed access t o he al thc ar e and in individuals with  
HIV .Â  Co-inf ection with HIV î‚’ Incr e ases the r isk of TB activ ation and mor t alit y  
signific antl y .Â  Mor t alit y W or ldwide î‚’ 6 million people die e v er y y e ar fr om c auses  
r elat ed t o or including TB.
3î‚’ High-Bur den Countr ies
Endemic R egions î‚’ TB is highl y pr e v alent in cer t ain countr ies.Â  K e y Countr ies î‚’  
India, China, Indonesia, Niger ia, and South Afr ic a account f or a signific ant  
pr opor tion of glob al TB c ases.Â  Geogr aphic Distr ibution î‚’ Incidence v ar ies  
gr e atl y , with Sub-Saharan Afr ic a and South Asia ha ving the highest rat es.Â  Risk  
F act ors : include migration fr om high-pr e v alence countr ies, age (abo v e 65î‚‚, and  
socioeconomic f act ors.
2î‚’ Risk F act ors and Vulnerable P opulations
T uber culosis
11î‚’ HIV and TB Co-Inf ection
Str ong Cor r elation î‚’ Ther e is a str ict cor r elation bet w een HIV and TB, as HIV  
incr e ases the r isk of TB r e activ ation.Â  Immunosuppr ession î‚’ HIV w e ak ens the  
immune syst em, incr e asing susceptibilit y t o TB.Â  T r eatment Challenges î‚’ Co-
inf ection complic at es tr e atment and incr e ases mor t alit y .Â  T esting f or HIV î‚’  
Essential in TB p atient s, especiall y in high-pr e v alence ar e as.Â  Ex ample î‚’ Ov er  
50% of TB p atient s in South Afr ic a ha v e HIV .
2î‚’ Other Immunosuppr essiv e F act ors
Immunosuppr ession î‚’ An y f act or that r educes immune function c an le ad t o TB  
r e activ ation.Â  Vit amin D Deficienc y î‚’ Lo w le v els of vit amin D cor r elat e with a  
higher r isk of tuber culosis, as vit amin D contr ols T -cell r esponses.Â  Age î‚’ The  
elder l y ar e at higher r isk due t o age-r elat ed immune decline.Â  CO VIDî‚ˆ19 Impact î‚’  
The CO VIDî‚ˆ19 p andemic r esul t ed in r educed TB notific ations and higher  
mor t alit y .
3î‚’ En vir onment al and Socioeconomic F act ors
Sunlight and TB î‚’ Ar e as with less sunlight ha v e higher TB incidence, cor r elating  
with vit amin D le v els.Â  Cr o w ded Living Conditions î‚’ Incr e ase TB transmission  
r isk.Â  Migr ation î‚’ Migrant s fr om high-pr e v alence countr ies ar e at incr e ased r isk,  
p ar ticular l y in the first y e ars af t er migration.
3î‚’ T r ends and Hist or ic al Dat a
Incidence T r ends î‚’ The glob al incidence of TB is f alling b y appr o ximat el y 2%  
annuall y .Â  Eur ope î‚’ Incidence is r elativ el y lo w , but East er n Eur ope has the highest  
numbers in the r egion.Â  I t al y î‚’ Lo w incidence countr y , but with pr e v alence in  
y oung migrant s and individuals o v er 65 .Â  Impact of CO VIDî‚ˆ19 î‚’ R eduction in TB  
notific ation rat es in some countr ies.Â  R eduction in TB Deaths î‚’ The "End TB  
Strat egy" aimed f or a 35% r eduction in TB de aths bet w een 2015 and 2020 .
ğŸ¦   M i c r o b i o l o g y  a n d  T r a n s m i s s i o n
This section f ocuses on the micr obiologic al aspect s ofÂ  M y cobact er ium  
tuber culosis Â and ho w the dise ase is transmit t ed.
1î‚’ Micr obiology ofÂ  M y cobact er ium tuber culosis
M y cobact er ium tuber culosis î‚MTBî‚‚ î‚’ The c ausativ e agent of tuber culosis.
1î‚’ MTB Comple x
T uber culosis
2MTB Comple x î‚’ A gr oup of closel y r elat ed m y cob act er ia.Â  Species î‚’ IncludesÂ  M.  
tuber culosis, M. bo vis, M. afr icanum, M. canet ti , and others.Â  M. bo vis î‚’ Pr imar il y  
transmit t ed thr ough cont act with inf ect ed co ws or ingestion of cont aminat ed  
dair y pr oduct s.Â  Int estinal TB î‚’ Of t en c aused b yÂ  M. bo vis Â due t o ingestion of  
cont aminat ed milk pr oduct s.
2î‚’ Bact er ial Charact er istics
R od-Shaped Bacillus :Â  M. tuber culosis Â is a r od-shaped b act er ium.Â  Non-Motile î‚’ I t  
does not mo v e independentl y .Â  Non-Spor ogenous î‚’ Does not f or m  
spor es.Â  Aer obic î‚’ R equir es o xy gen f or sur viv al and r eplic ation.Â  Intr acellular  
Sur viv al î‚’ Can sur viv e and r eplic at e within macr ophages.Â  Long R eplication  
Cy cle î‚’ Slo w gr o wth r esul t s in a long r eplic ation c y cle, r equir ing 30î‚ˆ 7 0 da ys f or  
cul tur e.
3î‚’ Cell W all Composition
Comple x Cell W all î‚’ The cell wall ofÂ  M. tuber culosis Â is comple x and  
waxy .Â  M y colic Acid î‚’ Cont ains m y colic acid, pr o viding r esist ance t o the immune  
syst em.Â  LAM Det ection î‚’ The pr esence of lipo arabinomannan î‚LAMî‚‚ c an be  
det ect ed in t est s.
2î‚’ Modes of T ransmission
A ir bor ne T r ansmission î‚’ TB is pr imar il y transmit t ed thr ough the air .Â  Dr oplet  
Nuclei î‚’ T ransmission occurs thr ough air bor ne p ar ticles.
1î‚’ A ir bor ne Par ticle Charact er istics
Big Dr oplet s î‚’ Can tra v el up t o 1 met er . ( e.g. meningitis fr omÂ  Neisser ia )Â  Small  
Dr oplet s î‚’ Can tra v el up t o 3 met ers ( e.g. TBî‚‚.Â  Inf ectious Dr oplet s î‚’ Can be  
viruses ( e.g. influenza) af f ecting an y one in the r oom.Â  P ar ticle W eight î‚’ A ir bor ne  
transmission depends on the w eight of the p ar ticles.
2î‚’ En vir onment al F act ors in T ransmission
En vir onment Mat t ers î‚’ T ransmission rat es ar e higher in cr o w ded and poor l y  
v entilat ed sp aces.Â  High-Risk Conditions î‚’ Include small r ooms, lack of fr esh air  
and sunlight.Â  Migr ation Cont e x t î‚’ Migrant s in the first f e w y e ars of t en liv e in  
conditions incr e asing transmission.
ğŸ›¡  P a t h o g e n e s i s  a n d  I m m u n e  R e s p o n s e
This section descr ibes the pr ogr ession of tuber culosis fr om inf ection t o  
dise ase, f ocusing on the immune r esponses in v ol v ed.
T uber culosis
31î‚’ Initial Inf ection and Phagoc y t osis
Inhalation of Dr oplet Nuclei î‚’ TB inf ection begins with the inhalation of dr oplet  
nuclei cont ainingÂ  M. tuber culosis .Â  Ciliar y Syst em î‚’ The ciliar y syst em in the  
r espirat or y tract t ypic all y e xpels the major it y î‚90%î‚‚ of inhaled dr oplet  
nuclei.Â  Al v eolar Spaces î‚’ The smallest p ar ticles î‚î‚—2 Âµm) r e ach the dist al al v eolar  
sp aces.Â  Macr ophages î‚’ The pr imar y cells in v ol v ed in the initial  
r esponse.Â  Phagoc y t osis î‚’ M y cob act er ia ar e engulf ed b y al v eolar macr ophages.
1î‚’ Macr ophage R esponse
L ysosomes and ROS î‚’ Macr ophages at t empt t o eliminat e the b act er ia using  
l ysosomes and r e activ e o xy gen species.Â  Chemokine Pr oduction î‚’ If  
macr ophages c annot eliminat e the b act er ia, the y pr oduce  
chemokines.Â  R ecruitment of Cells î‚’ These chemokines at tract other immune  
cells, p ar ticular l y other macr ophages.
2î‚’ Granuloma F or mation and Structur e
Gr anuloma F or mation î‚’ R ecruitment of immune cells le ads t o granuloma  
f or mation.Â  Gr anuloma î‚’ A structur e that walls of f the b act er ia, pr e v enting fur ther  
spr e ad.Â  Caseous Necr osis î‚’ The central r egion of a TB granuloma under goes  
c aseous necr osis.Â  Caseous Necr osis Descr iption î‚’ Macr ophages, inflammat or y  
cells, and b act er ia ar e depr iv ed of o xy gen.Â  Unique t o TB î‚’ Caseous necr osis is a  
hallmar k of TB granulomas, dif f er entiating them fr om those f or med in other  
dise ases.
1î‚’ Granuloma La y ers
Int er mediat e Str atum î‚’ Macr ophages and monoc y t es.Â  Ex t er nal Str atum î‚’  
Epithelioid and giant mul tinucle at ed cells.Â  Centr al Zone î‚’ Caseous Necr osis.
2î‚’ St abilit y and R e activ ation
Dynamic Structur e î‚’ The granuloma wall is const antl y r emodeled.Â  Immune  
Depr ession î‚’ The pr ocess is sensitiv e t o immune depr ession ( e.g., HIV ,  
cor ticost er oids).Â  Secondar y TB î‚’ Immune suppr ession allo ws m y cob act er ia t o  
r eplic at e, le ading t o secondar y TB.Â  Bef or e Immunosuppr essant s î‚’ Patient s must  
be t est ed f or HIV , TB, and syphilis.Â  R eactiv ation Risk î‚’ High if the immune  
syst em c annot maint ain the granuloma.
3î‚’ Immune R esponse Out comes
Ef f ectiv e R esponse î‚’ In the major it y of inf ect ed individuals, the macr ophages  
ef f ectiv el y cont ain the b act er ia, f or ming a granuloma, r esul ting in lat ent  
TB.Â  W eak R esponse î‚’ In 5î‚ˆ10% of inf ect ed individuals, the macr ophage  
T uber culosis
4r esponse is w e ak.Â  Immunosuppr essed Gr oups î‚’ Immunosuppr essed individuals  
and childr en under 5 y e ars ar e mor e lik el y t o ha v e a w e ak r esponse.Â  Pr imar y  
TB î‚’ The b act er ia spr e ads thr oughout the bod y .Â  Ex tr apulmonar y Manif est ations î‚’  
Pr imar y TB is associat ed with high amount s of e x trapulmonar y manif est ations  
( e.g., TB meningitis).Â  BCG V accine î‚’ Pr e v ent s pr imar y tuber culosis but does not  
pr e v ent secondar y tuber culosis.
ğŸ©º  C l i n i c a l  P r e s e n t a t i o n  o f  T u b e r c u l o s i s
This section co v ers the clinic al manif est ations of both pulmonar y and  
e x trapulmonar y TB.
1î‚’ Pulmonar y T uber culosis
Classical Pr esent ation î‚’ Pulmonar y TB of t en has an insidious onset and a  
chr onic course.Â  Chest Sympt oms î‚’ Cough ( of t en pr oductiv e ), hemopt ysis (lat e ),  
and chest p ain (usuall y pleur itic ).Â  Non-Specific Sympt oms î‚’ Nonspecific  
constitutional sympt oms ar e mor e common in childr en and HIV  
p atient s.Â  Ex tr apulmonar y Sympt oms î‚’ Ma y occur if the inf ection spr e ads be y ond
the lungs.
1î‚’ Sympt om Onset and Pr ogr ession
Subacut e Onset î‚’ Sympt oms de v elop graduall y .Â  Chr onic Natur e î‚’ Of t en  
charact er iz ed b y a pr olonged illness.Â  Dela y ed Diagnosis î‚’ The diagnosis in  
individuals bor n in I t al y is dela y ed mor e of t en than in those bor n abr o ad, due t o  
the chr onic and sub acut e onset.
2î‚’ Common Sympt oms
F e v er î‚’ Pr esent in 65î‚ˆ80% of c ases.Â  Chills/Night Sw eat s î‚’ Common  
sympt oms.Â  F atigue/Malaise î‚’ F r equentl y r epor t ed.Â  Anor e xia/W eight Loss î‚’  
T ypic al signs.Â  Asympt omatic Cases î‚’ 10î‚ˆ 20% of TB c ases ma y be asympt omatic  
at the time of diagnosis.
3î‚’ R adiologic al Findings
V ar ied Pr esent ation î‚’ The appe arance of TB on X -ra ys c an v ar y .Â  Budd y T r ee or  
Consolidation î‚’ X -ra ys ma y sho w a "budd y tr ee " p at t er n, r esembling b act er ial  
pneumonia.Â  Ca vit ation î‚’ Ca vities ma y be pr esent, indic ating ad v anced  
dise ase.Â  Dif f er ential Diagnosis f or Ca vit ation î‚’ NTM, fungi, c ancer , or pulmonar y  
v asculitis.Â  Ca vit ation and Hemopt ysis î‚’ Association with ad v anced st ages.
2î‚’ Ex trapulmonar y T uber culosis
T uber culosis
5Ex tr apulmonar y Disease î‚’ TB c an af f ect an y or gan or tissue out side of the  
lungs.
1î‚’ Miliar y T uber culosis
Disseminat ed TB î‚’ A se v er e f or m of TB, similar t o sepsis.Â  Spr ead î‚’ The inf ection  
spr e ads widel y thr ough the lungs, blood, and l ymph nodes.Â  R eticulonodular  
P at t er n î‚’ Charact er iz ed b y numer ous small nodules spr e ad thr oughout the  
lungs.Â  Emer genc y Condition î‚’ R equir es immediat e medic al  
at t ention.Â  Cont agious î‚’ Patient s ar e highl y cont agious.
2î‚’ TB L ymphadenitis
L ymph Node In v ol v ement î‚’ Pr imar il y af f ect s childr en.Â  Location î‚’ Commonl y  
infracla vicular , cer vic al, or submandibular .Â  Unilat er al vs. Bilat er al î‚’ Usuall y  
unilat eral; bilat eral in v ol v ement suggest s syst emic dise ase.Â  L ymph Node  
Char act er istics î‚’ Sof t, non-p ainful, and cold.Â  Abscess and Bact er ial  
L ymphadenoma î‚’ W ar m l ymph nodes, indic ating inflammation.Â  Diagnosis î‚’  
Biopsies, cul tiv ation, and det ection of TB in l ymph nodes.Â  Pr ognosis î‚’ Generall y  
consider ed a benign f or m with lo w mor t alit y .
3î‚’ TB Ser ositis
Ser osal In v ol v ement î‚’ Ser ous membranes (per ic ar dium, per it oneum, pleura) c an  
be af f ect ed.Â  Pleur itis î‚’ The most common f or m of ser ositis due t o it s association  
with the lungs.Â  Complications î‚’ P er ic ar ditis has ser ious  
complic ations.Â  Une xplained Ser ositis î‚’ Alwa ys consider TB.Â  Diagnosis î‚’  
Cul tiv ation of ser osal fluid t o det ect TB.
4î‚’ Other Ex trapulmonar y Sit es
Lar yngeal TB î‚’ Highl y cont agious.Â  Skin TB î‚’ Can pr esent with lesions, r equir ing  
biopsy f or diagnosis.Â  CNS TB î‚’ Includes TB meningitis, associat ed with the  
highest mor t alit y rat e.Â  TB Meningitis Sympt oms î‚’ Slo w onset with w eight loss  
and cranial ner v e p aral ysis.Â  H y dr ocephalus î‚’ Common due t o al t er ed CSF  
cir culation.Â  CSF Findings î‚’ Cle ar CSF with l ymphoc y t es, ele v at ed pr ot eins, and  
lo w glucose.Â  T uber culomas î‚’ Can c ause CNS sympt oms, identified via CT sc an  
or MRI.Â  Spine TB î‚’ Usuall y in the thoracic spine; P ot t's dise ase is mor e common  
in the lumb ar p ar t.Â  Genit our inar y TB î‚’ Can af f ect the genit al and ur inar y tract s.
ğŸ›¡  I m m u n e  R e c o n s t i t u t i o n  I n f l a m m a t o r y  S y n d r o m e  ( I R I S )
This section det ails the Immune R econstitution Inflammat or y Syndr ome î‚IRISî‚‚  
associat ed with TB.
T uber culosis
61î‚’ Definition and Mechanism
IRIS î‚’ An inflammat or y r esponse that occurs af t er the initiation of antir etr o viral  
therap y î‚ARTî‚‚.Â  P ar ado xical R eaction î‚’ Parado xic al inflammat or y r e action against  
a f or eign antigen (aliv e or de ad) in p atient s who ha v e st ar t ed ART and ha v e  
under gone r econstitution of their immune r esponses against this antigen.Â  HIV  
T r eatment î‚’ Occurs in p atient s with HIV who st ar t antir etr o viral therap y  
î‚ARTî‚‚.Â  Immune Syst em R eco v er y î‚’ The immune syst em is r est or ed af t er  
ART .Â  Inflammat or y R eaction î‚’ The r est or ed immune syst em o v er r e act s t o the  
m y cob act er ia.
1î‚’ Pathogenesis
Incr eased L ymphopr olif er ativ e R esponse î‚’ Incr e ased r esponse  
t oÂ  M y cobact er ium Â antigens in vitr o.Â  Cut aneous R esponse î‚’ R est oration of the  
cut aneous r esponse t o tuber culin.Â  Incr eased î‚ƒIL î‚ˆ6î‚„ î‚’ Incr e ased le v els of  
int er leukin-6 and activ ation mar k ers.Â  Genetic Associations î‚’ Associat ed with  
cer t ain genetic mar k ers ( e.g., TNF A î‚ˆ 308 1, IL6î‚ˆ17 4 Gî‚‚.
2î‚’ Clinic al Manif est ations and Examples
Clinical W orsening î‚’ Patient s e xper ience a w orsening of their condition af t er  
ART initiation.Â  T or ino Case 2 Ex ample î‚’ Case of a p atient with lo w CD4 cell  
count, initiall y sputum-negativ e f or TB.Â  T r eatment and R esponse î‚’ T r e atment of  
immunosuppr ession, which led t o an inflammat or y r e action af t er the immune  
syst em r eco v er ed.Â  IRIS F or ms : "Unmasking IRIS" and "W orsening IRIS" .
3î‚’ Management of IRIS
Unmasking IRIS î‚’ Pr esent s bef or e ART . R equir es diagnosis and tr e atment of the  
oppor tunistic inf ection.Â  W orsening IRIS î‚’ R equir es managing the  
inf ection.Â  NSAIDs î‚’ Ma y be used f or mild c ases.Â  Cor ticost er oids î‚’ Pr ednisone î‚1  
mg/k g) c an be used.Â  ART Consider ations î‚’ Int er ruption of ART in c ase of lif e-
thr e at ening or ser ious disor ders.Â  Monit or CD4 and Vir al Load î‚’ Monit or ing CD4  
count s and viral lo ad t o assess r esponse and manage tr e atment.
ğŸ§ª  D i a g n o s i s  a n d  T r e a t m e n t  o f  T B
This section addr esses the diagnostic methods and therapeutic appr o aches t o  
tuber culosis.
1î‚’ Diagnostic Appr o aches
Activ e and Lat ent TB î‚’ Distinguishing bet w een activ e and lat ent TB is  
crucial.Â  Activ e TB î‚’ Diagnosing activ e tuber culosis r equir es identifying the  
T uber culosis
7pr esence of the b act er ia.Â  Lat ent TB î‚’ R equir es det ecting e vidence of pr ior  
inf ection.
1î‚’ Activ e TB Diagnosis
Sampling Methods î‚’ Sputum, serum, or ur ine samples c an be used.Â  Cul tur e î‚’ The  
gold st andar d in micr obiology , r esul t s a v ailable within 14î‚ˆ15 da ys.Â  St aining î‚’  
Ziehl-Neelsen st aining c an quickl y identify TB b act er ia under a  
micr oscope.Â  PCR î‚’ P ol ymerase chain r e action î‚PCRî‚‚ is a rapid method.
2î‚’ Lat ent TB Diagnosis
Pur poses î‚’ T esting t o identify lat ent inf ections in migrant s or immunosuppr essed  
individuals.Â  Mant oux T est î‚’ Intrader mal injection of a pr ot ein fr omÂ  M.  
tuber culosis ; me asur ed b y p apule siz e.Â  P ositiv e R esul t î‚’ A p apule î‚˜1 cm is  
consider ed positiv e.Â  Limit ations î‚’ F alse positiv es due t o BCG  
v accination.Â  Int er f er on-Gamma R elease Assa ys î‚IGRAs) î‚’ Also kno wn as  
QuantiFERON, me asur es int er f er on-gamma pr oduction in r esponse t o TB  
antigens.Â  Specificit y î‚’ IGRAs ar e mor e specific.Â  Sensitivit y î‚’ T cells r e act t o TB  
antigens with v er y high sensitivit y .
3î‚’ T est Comp ar isons
F e atur e Mant oux T est î‚TSTî‚‚ Int er f er on-Gamma R ele ase Assa ys î‚IGRAî‚‚ ( e.g.,  
QuantiFERONî‚‚ T ype In viv o In vitr o Specificit y Less specific Mor e specific PPD  
PPD Boosting Specific antigens Patient Visit s 2 1 V ar iabilit y Int er -r e ader Lab  
v ar iabilit y R esul t s 2î‚ˆ 3 da ys 1 da y Phlebot om y No R equir ed P ositiv e Contr ol No  
Y es (+ contr ol)
2î‚’ T r e atment of Lat ent TB
Lat ent TB T r eatment î‚’ Not alwa ys r equir ed, as the r isk of r e activ ation is lo w .Â  Risk  
of R eactiv ation î‚’ 5î‚ˆ10% chance of r e activ ation.Â  Indications f or T r eatment î‚’  
Cer t ain gr oups ar e tr e at ed t o pr e v ent pr ogr ession.Â  T r eatment R egimen î‚’  
Isoniazid f or 6 months (with vit amin B6 f or pr egnant w omen), or r if ampin f or 4  
months.
1î‚’ High-Risk Gr oups f or Lat ent TB T r e atment
P eople Living with HIV î‚PLWHî‚‚ Â  R ecent Cont act s of TB Cases î‚’ Individuals  
e xposed t o TB.Â  Fibr otic Changes on Chest X -r a y î‚’ Sho wing old TB.Â  Or gan  
T r ansplant R ecipient s .Â  Immunosuppr essed Individuals î‚’ T aking high-dose  
cor ticost er oids or TNFî‚ˆÎ± ant agonist s.Â  High-Pr e v alence Countr ies î‚’ Individuals  
fr om these r egions.Â  Injection Drug Users .Â  High-Risk Congr egat e Set tings î‚’  
T uber culosis
8Cor r ectional f acilities, nursing homes, et c.Â  M y cobact er iology Labor at or y  
P ersonnel .Â  Childr en under 4 Y ears or Exposed t o High-Risk Adul t s .
3î‚’ Activ e TB T r e atment
Mul tidrug Ther ap y î‚’ The use of mul tiple drugs simul t aneousl y .Â  Drug R esist ance î‚’  
Due t o the het er ogeneous natur e of the b act er ial population.Â  Drug Choice  
R ationale î‚’ Isoniazid f or rapidl y gr o wing b act er ia, Pyrazinamide f or slo wl y  
gr o wing b act er ia, and Rif ampicin f or sporadic all y gr o wing b act er ia.
1î‚’ T r e atment R egimen
Initial Phase î‚’ F our drugs: Rif ampicin, Pyrazinamide, Ethambut ol, and Isoniazid  
f or 2 months.Â  Continuation Phase î‚’ Rif ampicin and Isoniazid f or 4  
months.Â  Cont agiousness R eduction î‚’ Af t er 2 w eeks of tr e atment,  
cont agiousness is appr o ximat el y 5%.Â  Dur ation of Ther ap y î‚’ Additional months  
ma y be r equir ed f or TB meningitis or bone dise ase.
2î‚’ Drug Doses and Side Ef f ect s
Common TB Drugs î‚’ Rif ampicin, Isoniazid, Ethambut ol, and  
Pyrazinamide.Â  Rif ampicin î‚10 mg/k g) î‚’ Orange ur ine and other bod y fluids,  
hep at ot o xicit y , CYP and P gP induction, and drug int eractions.Â  Isoniazid î‚  
Pyr ido xine î‚5 mg/k g) î‚’ Hep at ot o xicit y , per ipheral neur op ath y .Â  Ethambut ol î‚15î‚ˆ 20  
mg/k g) î‚’ Uv eitis, color blindness.Â  Pyr azinamide î‚20î‚ˆ 25 mg/k g) î‚’ Hep at ot o xicit y ,  
h yperur icemia.Â  Ethambut ol Not e î‚’ R e v ersible side ef f ect with e ar l y det ection, but
c an be ir r e v ersible in some p atient s.Â  Isoniazid î‚ B6 î‚’ Essential t o pr e v ent  
per ipheral neur op ath y .Â  Ef ficac y: Â The ef fic ac y of the 4 drug r egimen is usuall y  
95% but the true ef fic ac y is ar ound 85% due t o f act ors such as adher ence,  
side ef f ect s, et c.Â  HIV patient s î‚’ HIV p atient s ha v e a r e al ef fic ac y of 7 5%.Â  MDRî‚ˆ
TB ef ficac y î‚’ MDRî‚ˆ TB has an ef fic ac y of 50%.
4î‚’ Drug-R esist ant TB
MDRî‚ˆ TB î‚Mul ti-Drug R esist ant TBî‚‚ î‚’ R esist ant t o isoniazid and r if ampicin.Â  Global  
Pr e v alence î‚’ Af f ect s 3 . 1% of ne w c ases and 18% of pr e viousl y tr e at ed  
c ases.Â  XDRî‚ˆ TB î‚Ex t ensiv el y Drug-R esist ant TBî‚‚ î‚’ R esist ant t o fluor oquinolones  
and a gr oup A drug (bedaquiline or line z olid).Â  T r eatment f or R esist ant Str ains  
î‚P ast) î‚’ 5 t o 6 drugs f or 2 y e ars.Â  Ne w Guidelines f or R esist ant Str ains î‚’ 3î‚ˆ4 drugs  
f or 6 months (bedaquiline, pr et omanid, line z olid, and mo xiflo xacin)
ğŸ’¡  I m p o r t a n t  F a c t s  t o  M e m o r i z e
T uber culosis
9Glob al Bur den: Â TB is a le ading c ause of de ath w or ldwide, with  
appr o ximat el y 10 . 6 million activ e c ases annuall y .
HIV and TBî‚’ Â HIV signific antl y incr e ases the r isk of TB r e activ ation and  
mor t alit y , of t en coe xisting.
T r ansmission: Â Pr imar il y air bor ne, influenced b y dr oplet nuclei and  
en vir onment al f act ors such as cr o w ding and v entilation.
P at hogenesis: Â Granuloma f or mation is k e y , with c aseous necr osis in the  
cent er , which c an be compr omised b y immune deficiencies, le ading t o  
r e activ ation.
Clinic al Pr esent ation: Pulmonar y TBî‚’ Â Insidious onset, with cough,  
hemopt ysis, and pot ential f or c a vit ation.
Clinic al Pr esent ation: Ex tr apulmonar y TBî‚’ Â Miliar y TB is a se v er e  
disseminat ed f or m. TB l ymphadenitis in v ol v es cold, non-p ainful l ymph  
nodes.
IRISî‚’ Â Immune R econstitution Inflammat or y Syndr ome occurs af t er ART  
initiation in HIV p atient s, w orsening the condition.
Diagnosis: A ctiv e TBî‚’ Â R elies on sputum, serum, or ur ine samples; cul tur e  
and PCR ar e gold st andar ds.
Diagnosis: Lat ent TBî‚’ Â Diagnosed with Mant oux t est or IGRA, lik e  
QuantiFERON.
Lat ent TB T r e atment: Â R ecommended f or high-r isk gr oups î‚HIV , r ecent  
cont act s) with Isoniazid or Rif ampin.
A ctiv e TB T r e atment: Â Uses a 6-month, f our -drug r egimen: Rif ampicin,  
Pyrazinamide, Ethambut ol, and Isoniazid.
Drug Side Ef f ect s: Â Be awar e of Rif ampicin ( orange ur ine, hep at ot o xicit y),  
Isoniazid (per ipheral neur op ath y), Ethambut ol (visual distur b ances), and  
Pyrazinamide (hep at ot o xicit y , h yperur icemia).
MDRî‚ˆ TBî‚’ Â R esist ant t o isoniazid and r if ampicin.
XDRî‚ˆ TBî‚’ Â Ex tr emel y r esist ant; r equir es ne w er , shor t er tr e atment r egimens.
Risk F act ors f or r e activ ation: Â Immunosuppr ession fr om an y c ause  
(including HIV , st er oids, et c.) and Vit amin D deficienc y .
T uber culosis
10BCG V accine: Â Pr e v ent s pr imar y tuber culosis but not secondar y  
tuber culosis.
T uber culosis
11